Trump’s ‘TrumpRx’ Drug Discount Initiative and Pfizer Deal: A Look Back at the 2020 Announcement

In an effort to curb drug costs in the United States, then-President Donald Trump announced a comprehensive initiative, including the creation of a ‘TrumpRx’ direct-to-consumer website and a significant deal with pharmaceutical giant Pfizer. This announcement, made during his presidency, aimed to allow Americans to purchase medicines at discounted prices, with Trump declaring, “The United States is done subsidizing the health care of the rest of the world.”

Pfizer was the first drugmaker to align with Trump’s demands, agreeing to sell drugs to Medicaid at ‘Most Favored Nation’ levels—the lowest prices offered in peer countries. The agreement also included a 50% average discount on many primary care and some specialty brand-name drugs through the proposed TrumpRx site, which was slated to launch in early 2026. Additionally, Pfizer committed to expanding domestic manufacturing and received a three-year reprieve on certain pharmaceutical import tariffs.

The TrumpRx site, designed to redirect consumers to manufacturers’ direct-to-consumer channels rather than selling directly, was part of a broader push by the administration to pressure drugmakers on pricing. While the initiative was intended to lower costs for American patients, experts at the time raised questions about its potential impact, particularly concerning insurance coverage and the complex drug supply chain involving insurers and pharmacy benefit managers. The administration acknowledged that these actions might lead to price increases in other countries, which Trump deemed “fair.”

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.